- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Biosergen AB receives observation status | 261 | GlobeNewswire | On April 4, 2026, Biosergen AB ("the Company") disclosed that the Company's board of directors had resolved to pause the development of BSG005 and that the board of directors is exploring the possibility... ► Artikel lesen | |
| 04.04. | BIOSERGEN AB: Biosergen Pauses Development of BSG005 | 2 | Cision News | ||
| 10.02. | Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025 | 232 | GlobeNewswire (Europe) | February 10, 2026: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 01.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 01.12.2025 | 661 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.12.2025
Aktien
1 IT0005678104 Kaleon S.p.A.
2 IM00BYYPQX37... ► Artikel lesen | |
| 28.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.11.2025 | 1.219 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 28.11.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.11.2025ISIN NameCA38940L2057 GRAYCLIFF... ► Artikel lesen | |
| 28.11.25 | XFRA ISIN CHANGE | 531 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA60283T2074 Mineral Hill Industries Ltd. 28.11.2025 CA38077F1045 Gold Strategy Inc. 01.12.2025 Tausch 1:1US60855D3098 Moleculin... ► Artikel lesen | |
| 28.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2025 | 504 | Xetra Newsboard | Das Instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2025 und ex Kapitalmassnahme am 01.12.2025 The instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY is traded... ► Artikel lesen | |
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 27.11.25 | Reverse split and Change of ISIN for Biosergen AB | 365 | GlobeNewswire | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from Dec 1, 2025. The order book will not change.
Short... ► Artikel lesen | |
| 20.11.25 | Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen | 244 | GlobeNewswire (Europe) | STOCKHOLM, November 20, 2025. At the Annual General Meeting of Biosergen AB ("Biosergen" or the "Company") on June 11, 2025, a resolution was passed on a reverse split of shares, whereby one hundred... ► Artikel lesen | |
| 19.11.25 | Biosergen AB: Biosergen publishes interim report for the third quarter 2025 | 228 | GlobeNewswire (Europe) | November 19, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 20.08.25 | Biosergen AB: Biosergen publishes its interim report for the second quarter 2025 | 241 | GlobeNewswire (Europe) | Wednesday August 20, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the second quarter 2025. The interim report is available as an attached document and on... ► Artikel lesen | |
| 24.07.25 | Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer | 293 | GlobeNewswire (Europe) | Stockholm, Sweden - July 24, 2025 - Biosergen AB ("Biosergen" or the "Company"), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces the... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 34,160 | +0,09 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,650 | -0,07 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,620 | 0,00 % | Tango Therapeutics Shares Fall 17% | ||
| QIAGEN | 30,095 | +0,62 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 80,61 | 0,00 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| SUMMIT THERAPEUTICS | 17,475 | +0,03 % | Bernstein downgrades Summit Therapeutics stock rating on trial concerns | ||
| PRAXIS PRECISION MEDICINES | 350,56 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,010 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,110 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| NUVALENT | 101,24 | 0,00 % | Bernstein startet Coverage für Nuvalent mit "Outperform"-Rating und hohem Kursziel | ||
| ERASCA | 11,600 | -0,04 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EVOTEC | 5,080 | +3,67 % | Shortseller-Positionen aktuell: u.a. Evotec, FMC, Gerresheimer, Hypoport, Nagarro, Nordex, Suss MicroTec | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,570 | -0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,540 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| ALUMIS | 22,170 | 0,00 % | This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday |
BIOSERGEN AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -5,42 % bei einem Aktienkurs von 0,785 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.